Transparent leadership
At Photocure, we believe that a strong culture begins with its leadership. That is how we create a cohesive network of colleagues, working closely together towards the same goals. We believe in exercising the highest levels of accountability, integrity and transparency in order to succeed in our common goal of achieving the best healthcare for every patient with bladder cancer.
All members of Photocure’s Board of Directors are considered independent of the company’s senior management, material business contacts, and the company’s main shareholders. All board members are elected by shareholders through a General Meeting. For committee roles and biography details, please see below.
Board of Directors
Dylan Hallerberg, Chairperson of the Board
Independent board member Dylan Hallerberg is a private equity and investment executive with extensive experience operating, improving and investing in businesses across all asset classes and sectors. He started his career in investment banking at Moelis & Company Los Angeles, after which he worked at The Carlyle Group in London from 2010 to 2017, where he invested in European public and private markets with a heavy operational focus. Following Carlyle, Mr. Hallerberg continued his investment career as an Analyst/PM at GoldenTree Asset Management in London before transitioning to leadership roles at Arcturus UAV and Fortress Marine Anchors in the United States. He has extensive board experience, having served on several boards as a member, observer, or an executive. Dylan Hallerberg currently serves as the President and Owner of Fortress Marine Anchors and is an active real estate and private equity investor and family office advisor. Additionally, he serves on the board of Veterans Exploring Treatment Solutions (VETS), the leading veteran’s charity focused on serving Special Operations Forces (SOF) veterans suffering from TBI/CTE and PTSD. He graduated Summa Cum Laude with Highest Honors from University of California, Santa Barbara with a degree in Business Economics.
Dylan Hallerberg holds 150,000 shares and 36,390 share options in Photocure. He is an independent director, without material relationship with Photocure and being neither part of its executive team nor involved in the company’s day-to-day operations.
- Chairperson of the Compensation Committee
- Member of the Audit Committee.
Neal Shore, M.D., Director
Independent board member Dr. Shore is Medical Director for the Carolina Urologic Research Center and is a Fellow of the American College of Surgeons. He has conducted more than 400 clinical trials focusing mainly on genitourinary oncology. Dr. Shore performs peer reviews for Lancet Oncology, New England Journal of Medicine, European Urology, the Journal of Urology, Urology, BJUI, PCPD, and other high-impact scientific journals. He serves on the executive boards of the Society of Urologic Oncology and the Bladder Cancer Advocacy Network (BCAN). He has served as the National/Global Urology Research Director for GenesisCare from 2019-2023. From 2016 to 2018 Dr. Shore was the President of the Large Urology Group Practice Association. In addition, he has served on numerous Committees, Editorial and Review boards, such as the AUA Research and Innovations Committees, Health and Data Committees, the SITC Task Force for Prostate Cancer and Bladder Cancer, the Editorial Boards of Review in Urology, Urology Times, Chemotherapy Advisor, OncLive, PLOS ONE, Urology Practice, and the World Journal of Urology. Neal Shore holds no shares and 20,448 share options in Photocure.
He is an independent director, without material relationship with Photocure and being neither part of its executive team nor involved in the company’s day-to-day operations.
- Chairperson of the Scientific Committee
- Advisor for ESG matters.
Ghizlane Tagmouti, Director
Independent board member Ghizlane Tagmouti is an experienced investment professional with a background in mergers and acquisitions. She worked in the private equity team at Advent International in London from 2015 to 2024, and contributed to several of the firm's investments including the acquisition of ICE Pharma and Zentiva, where she served as a board member. Prior to Advent, Ms. Tagmouti was a member of the investment banking team at Morgan Stanley in Paris and London. She holds a Master Grande Ecole in Finance from ESCP Europe (France) and a Bachelor in Management from ISCAE (Morocco).
Ghizlane Tagmouti holds 25,000 shares and 16,475 share options in Photocure. She is an independent director, without material relationship with Photocure and being neither part of its executive team nor involved in the company’s day-to-day operations.
- Chairperson of the Audit Committee
- Member of the Compensation Committee.
Nomination Committee
Photocure has a Nomination Committee making recommendations to the general meeting regarding election of shareholder-elected members of the Board of Directors, remuneration to the members of the Board of Directors, election of members to the Nomination Committee and remuneration to the members of the Nomination Committee.
Robert Blatt (leader), Lars Viksmoen, Hans Peter Bøhn are current Nomination Committee members.
Please see the latest report of the Nomination Committee here.